• Molecular NameSulpiride
  • SynonymLevosulpirida [INN-Spanish]; Levosulpiride; Levosulpiride [INN]; Levosulpiridum [INN-Latin]; Sulpirid; Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpyrid
  • Weight341.432
  • Drugbank_IDDB00391
  • ACS_NO15676-16-1
  • Show 3D model
  • LogP (experiment)0.62
  • LogP (predicted, AB/LogP v2.0)0.77
  • pka8.9; 10.19
  • LogD (pH=7, predicted)-1.69
  • Solubility (experiment)0.454 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.2
  • LogSw (predicted, AB/LogsW2.0)4.61
  • Sw (mg/ml) (predicted, ACD/Labs)2.16
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds6
  • TPSA110.11
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-psychotic drug used mainly in the treatment of psychosis (e.g. schizophrenia) and depression.
  • Absorption_value40.0
  • Absorption (description)Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.
  • Caco_2-6.16
  • Bioavailability27.0
  • Protein binding40.0
  • Volume of distribution (VD)0.85 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeafter intravenous administration 4 to 13 h; after oral administration variously reported as 6 to 15 h (mean 10) and 13 to 41 h (mean 25).
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50>3000